A new analysis of multiple myeloma clinical trials from 2014 to 2024 found CAR-T therapies now dominate pipeline activity, representing 46.8% of studies listed on ClinicalTrials.gov and in Cortellis Drug Discovery Intelligence. The work also reported that small molecules account for 31% of trials and T-cell-engaging antibodies for 16%, while annual trial growth accelerated after 2020. The authors attribute momentum to evolving regulatory pathways, including FDA’s accelerated approval mechanism. For pipeline strategists, the findings frame how sponsor prioritization is shifting toward cell-based modalities for myeloma target discovery and regimen expansion.